Fan M, Ma Y, Deng G, Si H, et al. A real-world analysis of second-line treatment option, Gemcitabine plus Anlotinib and anti-PD1, in advanced pancreatic cancer. Pancreatology 2024 Mar 25:S1424-3903(24)00078-4. doi: 10.1016/j.pan.2024.
PMID: 38553260